Subcutaneous Amifostine (Ethyol®) in the Prevention of Radiochemotherapy-Induced Esophagitis and Pneumonitis in Patients With Unresectable Non-Small Cell Lung Cancer
- Conditions
- EsophagitisPneumonitisNon-Small Cell Lung Carcinoma
- Registration Number
- NCT00081315
- Lead Sponsor
- MedImmune LLC
- Brief Summary
The primary objective of this study is to assess the activity of subcutaneous (SC) amifostine on the incidence and severity of acute radiochemotherapy-induced esophagitis in patients with unresectable Stage IIIA or IIIB non-small cell lung cancer (NSCLC) receiving combined modality therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 130
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method - Acute radiochemotherapy-induced esophagitis will be assessed from the time of randomization through up to 3 months after completion of radiochemotherapy treatment.
- Secondary Outcome Measures
Name Time Method - Acute radiochemotherapy-induced pneumonitis will be assessed until 6 months after the last dose of XRT.
Trial Locations
- Locations (24)
Cedars Sanai
🇺🇸Los Angeles, California, United States
Radiation Oncology Center
🇺🇸Sacramento, California, United States
The Center for Cancer Care
🇺🇸Torrington, Connecticut, United States
Florida Wellcare Alliance
🇺🇸Inverness, Florida, United States
Florida Community Cancer Center
🇺🇸New Port Richey, Florida, United States
Ormand Memorial Cancer Center
🇺🇸Ormand Beach, Florida, United States
Sarasota Memorial Hospital
🇺🇸Sarasota, Florida, United States
University Community Hospital-Center for Cancer Care
🇺🇸Tampa, Florida, United States
University of Kentucky
🇺🇸Lexington, Kentucky, United States
St. Agnes Health Care
🇺🇸Baltimore, Maryland, United States
Scroll for more (14 remaining)Cedars Sanai🇺🇸Los Angeles, California, United States